Elemer Piros

Despite confirming third-quarter catalysts and progress throughout its development pipeline, Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)’s first-quarter financial report didn’t impress investors. The company conceded an 8.3-percent stock decline Tuesday even as it boasts a 22-percent...

Quarterly earnings reports matter a lot more for some companies than others. According to Wall Street analysts, investors should look beyond Bellicum Pharmaceuticals Inc (NASDAQ: BLCM)’s first-quarter earnings miss and focus on its drug pipeline, which includes leading cancer treatment...

Ocular Therapeutix Inc (NASDAQ: OCUL) shares sunk nearly 16 percent following a first-quarter earnings miss Friday. Despite the shares' current weakness, Cantor Fitzgerald reiterated its Overweight rating on the company with a $35 price target, well above Friday's $8. Analyst's Take On Earnings,...

Commenting on the first-quarter results of Glaukos Corp (NYSE: GKOS), Cantor Fitzgerald reiterated its Overweight rating and a 12-month price target of $54. The firm also opined that growth will continue in 2017. Q1 Print Analysts Elemer Piros and Justin Kim noted the first quarter marked the 15th...

Elemer Piros of Cantor Fitzgerald maintains an Overweight rating on Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)'s stock with a $14 price target after the company reported data from a Phase 2b study, which helped boost the stock higher by more than 5 percent. During the National Kidney Foundation...

Having demonstrated efficacy in its Phase 2b AURA-LV study for patients with active lupus nephritis, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)'s voclosporin appears “well-positioned in late-stage development to succeed,” Cantor Fitzgerald’s Elemer Piros said in a report. Piros...

Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) has received a price target increase to $24 from $17 from Cantor Fitzgerald, which reiterated an Overweight rating following positive data from the company’s Phase 2 study in Cystic Fibrosis. “Treatment with anabasum at the highest dose...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) is about to embark upon a journey with unknown destinations, as investors brace for a trio of reads from the company in the third quarter of 2017. Focus: 3 Phase 2 Reads Of ZYN002 Cantor Fitzgerald said in a note released Monday it remains focused on...

Cantor Fitzgerald’s Elemer Piros believes Global Blood Therapeutics Inc’s (NASDAQ: GBT) lead pipeline candidate, GBT440, “has demonstrated compelling potential for the treatment of sickle cell disease (SCD), based on its reported clinical efficacy and safety data.” The...

Cantor Fitzgerald reiterated its Overweight rating on Aerie Pharmaceuticals Inc (NASDAQ: AERI) as the company prepares for commercialization of Rhopressa for a potential approval in early 2018. Aerie had resubmitted the Rhopressa NDA in February, and Cantor Fitzgerald's analyst believes Rhopressa...

A conference call with cystic fibrosis specialists indicated that the disease continued to be characterized by “a vicious cycle of mucus secretion, infection and inflammation,” Cantor Fitzgerald’s Elemer Piros said in a report. He added that the call reinforced “our view...

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) hosted a call on Friday to divulge information about changes it made to a late-stage REGENERATE study in Nonalcoholic steatohepatitis, or NASH. Following the call, sell-side analysts gave contrasting views on the development. The Amendments The...

Elemer Piros of Cantor Fitzgerald maintains an Overweight rating on GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) with a $208 price target following the company's "encouraging" Phase 2 glioama data report. Success In GBM As part of the Phase 2 study, 21 patients who were treated with GW's mixed THC:CD...

Cantor Fitzgerald said in a note on Tuesday Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) is poised to have three data readouts in the first half of 2017. Analyst Elemer Piros noted that the company reported the initiation of its FAB-C Phase II study with ZYN002 in children with Fragile X...

Cantor Fitzgerald’s Elemer Piros noted that Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) will have three ongoing Phase II programs by the end of the year for its lead candidate ZYN002, a transdermal synthetic cannabidiol (CBD), with results expected in the first half of 2017, which could...